Corbus Pharmaceuticals(US:CRBP) ZACKS·2025-03-13 17:14Core Viewpoint - Corbus Pharmaceuticals (CRBP) has received a Zacks Rank upgrade to 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a stock's fair value, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Outlook - Corbus Pharmaceuticals is projected to earn -$6.14 per share for the fiscal year ending December 2025, reflecting a year-over-year decline of 66.9% [8]. - Over the past three months, the Zacks Consensus Estimate for Corbus Pharmaceuticals has increased by 2.4%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - The upgrade to Zacks Rank 2 places Corbus Pharmaceuticals in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].